Sonepcizumab

CAS No. 1031360-18-5

Sonepcizumab( —— )

Catalog No. M36735 CAS No. 1031360-18-5

Sonepcizumab (LT 1009) is a fully humanized monoclonal antibody against S1P, with anti-cancer activity, useful for studying metastatic renal cell carcinoma (mRCC) and preventing eye scarring after glaucoma filtration surgery.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 439 Get Quote
5MG 629 Get Quote
10MG 847 Get Quote
25MG 1242 Get Quote
50MG 1674 Get Quote
100MG 2205 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Sonepcizumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Sonepcizumab (LT 1009) is a fully humanized monoclonal antibody against S1P, with anti-cancer activity, useful for studying metastatic renal cell carcinoma (mRCC) and preventing eye scarring after glaucoma filtration surgery.
  • Description
    Sonepcizumab (LT 1009) is a fully humanized anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    LPL Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1031360-18-5
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Pal SK, et al. A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma. Cancer. 2017 Feb 15;123(4):576-582.?
molnova catalog
related products
  • Bretazenil

    Bretazenil is a GABAA benzodiazepine site partial agonist. Bretazenil shows an EC50 of 10 nM for recombinant α1β1γ2.

  • 1-Benzyl-4-hydroxypi...

    Compound Fr12729 is a useful organic compound for research related to life sciences.

  • DZ2002

    DZ2002, an orally active, reversible, and low-cytotoxic type III SAHH inhibitor (Ki=17.9 nM), exhibits significant immunosuppressive activity.